Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

J. M. Burns, L. D. Cornell, D. K. Perry, H. S. Pollinger, J. M. Gloor, Walter K Kremers, M. J. Gandhi, P. G. Dean, Mark D Stegall

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

We examined the course of donor-specific alloantibody (DSA) levels early after transplant and their relationship with acute humoral rejection (AHR) in two groups of positive crossmatch (+XM) kidney transplant recipients: High DSA group - 41 recipients with a baseline T- or B-cell flow crossmatch (TFXM, BFXM) channel shift ≥300 (molecules of equivalent soluble fluorochrome units (MESF) of approximately 19 300) who underwent pretransplant plasmapheresis (PP), and Low DSA group - 29 recipients with a baseline channel shift <300 who did not undergo PP. The incidence of AHR was 39% (16/41) in the High DSA group and 31% (9/29) in the Low DSA group. Overall, mean DSA levels decreased by day 4 posttransplant and remained low in patients who did not develop AHR. By day 10, DSA levels increased in patients developing AHR with 92% (23/25) of patients with a BFXM >359 (MESF of approximately 34 000) developing AHR. The BFXM and the total DSA measured by single antigen beads correlated well across a wide spectrum suggesting that either could be used for monitoring. We conclude that AHR is associated with the development of High DSA levels posttransplant and protocols aimed at maintaining DSA at lower levels may decrease the incidence of AHR.

Original languageEnglish (US)
Pages (from-to)2684-2694
Number of pages11
JournalAmerican Journal of Transplantation
Volume8
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Isoantibodies
Kidney Transplantation
Tissue Donors
Fluorescent Dyes
Plasmapheresis
B-Lymphocytes
Transplants
Kidney
Antigens
Incidence

Keywords

  • Acute humoral rejection
  • Alloantibody
  • Human leukocyte antigen
  • Kidney transplant
  • Positive crossmatch
  • Single antigen beads

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. / Burns, J. M.; Cornell, L. D.; Perry, D. K.; Pollinger, H. S.; Gloor, J. M.; Kremers, Walter K; Gandhi, M. J.; Dean, P. G.; Stegall, Mark D.

In: American Journal of Transplantation, Vol. 8, No. 12, 12.2008, p. 2684-2694.

Research output: Contribution to journalArticle

Burns, J. M. ; Cornell, L. D. ; Perry, D. K. ; Pollinger, H. S. ; Gloor, J. M. ; Kremers, Walter K ; Gandhi, M. J. ; Dean, P. G. ; Stegall, Mark D. / Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. In: American Journal of Transplantation. 2008 ; Vol. 8, No. 12. pp. 2684-2694.
@article{77722eb30267458db407b22f26d41948,
title = "Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation",
abstract = "We examined the course of donor-specific alloantibody (DSA) levels early after transplant and their relationship with acute humoral rejection (AHR) in two groups of positive crossmatch (+XM) kidney transplant recipients: High DSA group - 41 recipients with a baseline T- or B-cell flow crossmatch (TFXM, BFXM) channel shift ≥300 (molecules of equivalent soluble fluorochrome units (MESF) of approximately 19 300) who underwent pretransplant plasmapheresis (PP), and Low DSA group - 29 recipients with a baseline channel shift <300 who did not undergo PP. The incidence of AHR was 39{\%} (16/41) in the High DSA group and 31{\%} (9/29) in the Low DSA group. Overall, mean DSA levels decreased by day 4 posttransplant and remained low in patients who did not develop AHR. By day 10, DSA levels increased in patients developing AHR with 92{\%} (23/25) of patients with a BFXM >359 (MESF of approximately 34 000) developing AHR. The BFXM and the total DSA measured by single antigen beads correlated well across a wide spectrum suggesting that either could be used for monitoring. We conclude that AHR is associated with the development of High DSA levels posttransplant and protocols aimed at maintaining DSA at lower levels may decrease the incidence of AHR.",
keywords = "Acute humoral rejection, Alloantibody, Human leukocyte antigen, Kidney transplant, Positive crossmatch, Single antigen beads",
author = "Burns, {J. M.} and Cornell, {L. D.} and Perry, {D. K.} and Pollinger, {H. S.} and Gloor, {J. M.} and Kremers, {Walter K} and Gandhi, {M. J.} and Dean, {P. G.} and Stegall, {Mark D}",
year = "2008",
month = "12",
doi = "10.1111/j.1600-6143.2008.02441.x",
language = "English (US)",
volume = "8",
pages = "2684--2694",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

AU - Burns, J. M.

AU - Cornell, L. D.

AU - Perry, D. K.

AU - Pollinger, H. S.

AU - Gloor, J. M.

AU - Kremers, Walter K

AU - Gandhi, M. J.

AU - Dean, P. G.

AU - Stegall, Mark D

PY - 2008/12

Y1 - 2008/12

N2 - We examined the course of donor-specific alloantibody (DSA) levels early after transplant and their relationship with acute humoral rejection (AHR) in two groups of positive crossmatch (+XM) kidney transplant recipients: High DSA group - 41 recipients with a baseline T- or B-cell flow crossmatch (TFXM, BFXM) channel shift ≥300 (molecules of equivalent soluble fluorochrome units (MESF) of approximately 19 300) who underwent pretransplant plasmapheresis (PP), and Low DSA group - 29 recipients with a baseline channel shift <300 who did not undergo PP. The incidence of AHR was 39% (16/41) in the High DSA group and 31% (9/29) in the Low DSA group. Overall, mean DSA levels decreased by day 4 posttransplant and remained low in patients who did not develop AHR. By day 10, DSA levels increased in patients developing AHR with 92% (23/25) of patients with a BFXM >359 (MESF of approximately 34 000) developing AHR. The BFXM and the total DSA measured by single antigen beads correlated well across a wide spectrum suggesting that either could be used for monitoring. We conclude that AHR is associated with the development of High DSA levels posttransplant and protocols aimed at maintaining DSA at lower levels may decrease the incidence of AHR.

AB - We examined the course of donor-specific alloantibody (DSA) levels early after transplant and their relationship with acute humoral rejection (AHR) in two groups of positive crossmatch (+XM) kidney transplant recipients: High DSA group - 41 recipients with a baseline T- or B-cell flow crossmatch (TFXM, BFXM) channel shift ≥300 (molecules of equivalent soluble fluorochrome units (MESF) of approximately 19 300) who underwent pretransplant plasmapheresis (PP), and Low DSA group - 29 recipients with a baseline channel shift <300 who did not undergo PP. The incidence of AHR was 39% (16/41) in the High DSA group and 31% (9/29) in the Low DSA group. Overall, mean DSA levels decreased by day 4 posttransplant and remained low in patients who did not develop AHR. By day 10, DSA levels increased in patients developing AHR with 92% (23/25) of patients with a BFXM >359 (MESF of approximately 34 000) developing AHR. The BFXM and the total DSA measured by single antigen beads correlated well across a wide spectrum suggesting that either could be used for monitoring. We conclude that AHR is associated with the development of High DSA levels posttransplant and protocols aimed at maintaining DSA at lower levels may decrease the incidence of AHR.

KW - Acute humoral rejection

KW - Alloantibody

KW - Human leukocyte antigen

KW - Kidney transplant

KW - Positive crossmatch

KW - Single antigen beads

UR - http://www.scopus.com/inward/record.url?scp=55949096202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949096202&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02441.x

DO - 10.1111/j.1600-6143.2008.02441.x

M3 - Article

VL - 8

SP - 2684

EP - 2694

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -